Get the Stockscreener App
17.49
0.06%
-0.01
After Hours:
17.49
Vtv Therapeutics Inc stock is traded at $17.49, with a volume of 1,137.
It is down -0.06% in the last 24 hours and down -3.90% over the past month.
See More
Previous Close:
$17.50
Open:
$16.6605
24h Volume:
1,137
Relative Volume:
0.05
Market Cap:
$45.69M
Revenue:
$5.02M
Net Income/Loss:
$-18.31M
P/E Ratio:
-3.8609
EPS:
-4.53
Net Cash Flow:
$-23.40M
1W Performance:
+1.98%
1M Performance:
-3.90%
6M Performance:
+23.17%
1Y Performance:
-30.35%
1-Day Range:
$16.66
$17.49
1-Week Range:
$16.40
$17.86
52-Week Range:
$12.12
$29.19
Vtv Therapeutics Inc Stock (VTVT) Company Profile
Name
Vtv Therapeutics Inc
Sector
Industry
Phone
336-841-0300
Address
3980 PREMIER DR, HIGH POINT, NC
Compare VTVT with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
VTVT
Vtv Therapeutics Inc
|
17.49 | 45.69M | 5.02M | -18.31M | -23.40M | -4.53 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.01 | 124.29B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
610.64 | 68.39B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
590.06 | 35.99B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
262.16 | 33.93B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
264.32 | 28.47B | 3.81B | -644.79M | -669.77M | -6.24 |
Vtv Therapeutics Inc Stock (VTVT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-30-19 | Initiated | H.C. Wainwright | Buy |
| Apr-10-18 | Downgrade | Stifel | Buy → Hold |
| Mar-08-18 | Initiated | ROTH Capital | Buy |
| Feb-08-18 | Initiated | Northland Capital | Outperform |
| Sep-26-16 | Initiated | H.C. Wainwright | Buy |
| Sep-04-15 | Initiated | Canaccord Genuity | Buy |
| Aug-24-15 | Initiated | Piper Jaffray | Overweight |
| Aug-24-15 | Initiated | Stifel | Buy |
View All
Vtv Therapeutics Inc Stock (VTVT) Latest News
vTv Therapeutics (NASDAQ:VTVT) Now Covered by StockNews.com - Defense World
(VTVT) Trading Signals - Stock Traders Daily
vTv Therapeutics Inc Reports Q4 2024 EPS of -$0.55, Beating Esti - GuruFocus.com
vTv Therapeutics Announces 2024 Fourth Quarter and Full Year Financial Results and Provides Corporate Update - GlobeNewswire
The Zacks Analyst Blog Highlights Sarepta Therapeutics, Incyte, Gilead Sciences and VTv Therapeutics - Yahoo Finance
VTv Therapeutics: Q4 Earnings Snapshot - CTPost
VTv Therapeutics: Q4 Earnings Snapshot -March 20, 2025 at 06:02 pm EDT - Marketscreener.com
vTv Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView
FDA Greenlights vTv Diabetes Drug Trial as Cash Reserves Triple to $36.7M - StockTitan
vTv Therapeutics Inc. (VTVT) reports earnings - Quartz
Why Celsius Holdings Stock Popped This Week - The Globe and Mail
Biotech Stock Roundup: Patient Death Hits SRPT, INCY Study Data & More - Zacks Investment Research
Short Interest in vTv Therapeutics Inc. (NASDAQ:VTVT) Decreases By 13.6% - Defense World
12 Health Care Stocks Moving In Wednesday's Intraday Session - Benzinga
Biotech Alert: Searches spiking for these stocks today - TipRanks
StockNews.com Begins Coverage on vTv Therapeutics (NASDAQ:VTVT) - Defense World
vTv Therapeutics Soars 43% as FDA Lifts Clinical Hold on Diabetes Drug Trial - GuruFocus.com
Healthcare Up as Traders Rotate to Less Inflation-Sensitive Sectors -- Health Care Roundup - MarketScreener
Sector Update: Health Care Stocks Rise Late Afternoon - TradingView
Sector Update: Health Care -March 17, 2025 at 03:39 pm EDT - Marketscreener.com
FDA Lifts Clinical Hold On vTv Therapeutics' Phase 3 Diabetes Trial, Stock Surges - Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session - Benzinga
FDA Lifts Clinical Hold, vTv Therapeutics (VTVT) Stock Surges - Stocks Telegraph
vTv Therapeutics up after FDA lifts clinical hold on its oral diabetes treatment study - Seeking Alpha
vTv Therapeutics resumes phase 3 diabetes trial By Investing.com - Investing.com Australia
VTv Therapeutics Says FDA Lifted Clinical Hold On Cadisegliatin Program For Diabetes - Nasdaq
vTv Therapeutics stock surges on FDA update By Investing.com - Investing.com Canada
Vtv Therapeutics Says FDA Lifts Clinical Hold on Cadisegliatin Program for Diabetes; Shares Up Pre-Bell - Marketscreener.com
vTv Therapeutics stock surges on FDA update - Investing.com
vTv Therapeutics resumes phase 3 diabetes trial - Investing.com
vTv Therapeutics Announces Resumption of CATT1 Phase 3 Trial for Cadisegliatin as Potential First Oral Adjunct Therapy for Type 1 Diabetes - Nasdaq
vTv Therapeutics Announces FDA has Lifted Clinical Hold on Cadisegliatin Program for Diabetes - The Manila Times
FDA Green Light: vTv's Revolutionary Oral Diabetes Drug Back on Track with Faster Timeline - StockTitan
3 Quality Compounders on Our Buy List - The Globe and Mail
vTv Therapeutics Stock Price, Quotes and Forecasts | NASDAQ:VTVT - Benzinga
vTv Therapeutics Inc expected to post a loss of 87 cents a shareEarnings Preview - TradingView
vTv Therapeutics (VTVT) Projected to Post Quarterly Earnings on Tuesday - Defense World
Long Term Trading Analysis for (VTVT) - Stock Traders Daily
vTv Therapeutics CFO to Resign in March By Investing.com - Investing.com Canada
vTv Therapeutics CFO to Resign in March - Investing.com
vTv Therapeutics CFO Steven Tuch to Resign - TipRanks
vTv Therapeutics (NASDAQ:VTVT) Coverage Initiated at StockNews.com - Defense World
Vtv Therapeutics Inc Stock (VTVT) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.23%
1.63%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):